Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

L.A. McKeown

June 23, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

Silent MI Often Precedes Sudden Cardiac Death, Finnish Data Confirm

Caitlin E. Cox

July 15, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

News Daily News

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

L.A. McKeown

August 09, 2018

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Silent MI Often Precedes Sudden Cardiac Death, Finnish Data Confirm

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content